Humacyte develops bioengineered vascular grafts for the treatment of vascular diseases and the replacement of anatomical conduits. Their products aim to provide durable, off-the-shelf solutions that enhance patient outcomes by reducing the need for donor tissue and minimizing complications associated with traditional grafts.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Vascular trauma often requires immediate intervention to restore blood flow and prevent limb loss, but the current gold standard, autologous vein grafts, are not always feasible due to vein damage, absence, or the need for a second surgical site, adding time and potential complications. Synthetic grafts carry a higher risk of infection, particularly in contaminated wounds.
Solution
Humacyte provides SYMVESS™, an off-the-shelf, bioengineered human acellular tissue engineered vessel (ATEV) for vascular trauma repair. SYMVESS™ is designed to be universally implantable as a vascular conduit for extremity arterial injury when urgent revascularization is needed and an autologous vein graft is not feasible. The ATEV platform is designed to restore blood flow post-implantation and repopulate with the patient’s own cells, and has demonstrated high patency and low rates of amputation and infection in clinical studies.
Target Audience
Vascular and trauma surgeons at Level 1 Trauma centers and hospitals treating patients with severe limb-threatening and life-threatening extremity arterial injuries are the primary users.
Features
- Universally implantable, human-derived biologic vessel
- Acellular design intended to repopulate with the patient’s cells
- Demonstrated low susceptibility to infection compared to synthetic grafts
- No immune response observed in clinical studies
- Available off-the-shelf, eliminating the need for vein harvesting
- Designed for consistent and predictable performance